GF 107
Alternative Names: GF-107Latest Information Update: 28 Jul 2023
At a glance
- Originator GenFleet Therapeutics
- Class Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for research development in Autoimmune-disorders in China
- 20 Jun 2019 Early research in Autoimmune disorders in China before June 2019 (GenFleet Therapeutics pipeline, June 2019)